El interés en corto de Cue Biopharma da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Cue Biopharma. Los datos de interés en corto se actualizan cada dos semanas.

Cue Biopharma (NASDAQ:CUE) Bolsa, Informe de interés en corto

Cue Biopharma

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Cue Biopharma Inc

Cuentas Inc

COPPEREX RES CORP by COPPEREX RES CORP

CUE ENERGY RESOURCES LTD by Cue Energy Resources Ltd.

Three <a href="https://www.benzinga.com/etfs">healthcare-themed ETFs</a> were in sharp spotlight Thursday as the sector got through a wild trading day, fueled by UnitedHealth&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) earnings disappointment and steep stock decline. While insurers weighed down on broad healthcare gauges, a drugmakers rally, led by Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), limited the damage.
Also Read: <a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">UnitedHealth CEO Says High Cost Of US Health Care &#8216;Simply Not Sustainable&#8217;</a>
ETFs In Spotlight
Health Care Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)
<ol>
<li></li>
</ol>
1-Day Return (Thursday): -0.6%
Top holdings of this fund are Eli Lilly, UnitedHealth, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>). UnitedHealth dropped 2.4%, spooking XLV early in the session. The ETF trimmed losses, however, as Eli Lilly rallied 14.3% on <a href="https://www.benzinga.com/general/biotech/25/04/44878381/eli-lilly-rallies-over-14-notches-best-day-since-june-2000-on-oral-weight-loss-drug-results-analysts-react">good weight-loss pill trial news</a>, calling out the group&#8217;s internal divergency. Barring Thursday&#8217;s turmoil, though, XLV is off just 1.5% for the year so far and commands a 17x forward-earnings multiple—below its five-year history and the large-cap S&amp;P 500&#8217;s 20x multiple, according to Barron&#8217;s.
iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)
<ol start="2">
<li></li>
</ol>
1-Day Performance: +4.6%
IHE surged as investors rotated into large-cap pharma stocks, bolstered by Eli Lilly's rally. The gains came despite a nearly 8% drop in Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Lilly's rival in the GLP-1 space.
SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)
<ol start="3">
<li></li>
</ol>
1-Day Performance: +2.15%
XPH tracked gains across a broader basket of pharmaceutical names, benefiting from bullish sentiment on drugmakers following Lilly's breakthrough.
Market Context: A Sector Of Contrasts
UnitedHealth&#8217;s <a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">poor earnings and soft guidance</a> spooked healthcare investors, highlighting how exposed insurers are to firm-specific disappointments and policy-level risks. The 22% decline in the stock not only heavily burdened XLV—where it is the second-largest position—but pulled down peers CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) too.
However, the overall message of the day was one of subtlety and not panic. Eli Lilly&#8217;s explosion proved the influence of innovation in developing market-driving catalysts within the health-care sector. It provided the stimulus that helped neutralize weakness within managed care and indicated how investors in ETFs are able to still uncover segments of strength despite sector-wide selloffs.
At the same time, Johnson &amp; Johnson kept its steady pace going with the help of strong earnings.
Device and medical equipment manufacturers like Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), Zimmer Biomet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>), and Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) are also attracting investor attention as Wall Street is wagering on secular demand from the aging population.
Takeaway
The health care industry remains far from monolithic. Thursday&#8217;s ETF action underscored the increasing divide between pressured insurers and pharma names benefiting from innovation tailwinds. For investors in ETFs, the message is simple: thematic selectivity is key. Though political headlines and earnings fluctuations might continue to shock portions of the industry, solid fundamentals within pharma and medtech imply there&#8217;s still ample healthy opportunity to go around.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44876466/the-10k-handbag-hoax-tiktoks-trade-war-puts-luxury-etfs-in-the-hot-seat">The $10K Handbag Hoax? TikTok&#8217;s Trade War Puts Luxury ETFs In The Hot Seat</a></li>
</ul>
Image: Shutterstock/The Image Party

Sector ETFs

ETFs

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Dow Jones US Pharmaceuticals Index Fund

ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot

<a href="https://www.bloomberg.com/news/articles/2025-04-18/boeing-begins-flying-back-planes-destined-for-chinese-airlines">https://www.bloomberg.com/news/articles/2025-04-18/boeing-begins-flying-back-planes-destined-for-chinese-airlines</a>

News

General

'Boeing Begins Flying Back Planes Destined For Chinese Airlines'- Bloomberg

Mark Cuban isn't interested in patching up the healthcare system with duct tape and buzzwords. He wants to rip it open, throw it under a spotlight, and ask what a lot of Americans are already thinking: Why is this entire industry allowed to operate in complete darkness?
In a February <a href="https://hospitalogy.com/articles/2025-04-04/i-just-wanna-fck-up-healthcare/">fireside chat</a> with Hospitalogy founder Blake Madden—later revisited in April—the billionaire behind Cost Plus Drugs didn't hold back. He took aim at insurance companies, hospitals, consultants, and just about anyone profiting off the confusion. And yes, he said it: "I don't think there's a reason that health insurance should exist."
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Invest in the future of digital engagement: <a href="https://www.benzinga.com/money/vatom-adv">Own a piece of the $100 billion Metaverse for just $500</a>.</li>
</ul>
Cuban's not looking to <a href="https://www.benzinga.com/25/02/43932776/mark-cuban-slams-fd-up-healthcare-system-blames-insurance-designed-deductibles-for-patient-bankruptcy">compete with insurers</a>. He just wants to make them irrelevant. "We're going to try to make it so that self-insured employers have no reason to work with insurance companies," he said. In his view, insurers approve plans that restrict access and bury costs behind layers of red tape. Worse, they don't even ask the most basic questions.
"Why is the health of our entire country based on providers who don't know their own f&#x2A;cking costs?" he asked.
Hospitals don't get a pass either. Cuban blasted their refusal to publish general ledgers or disclose what procedures and services actually cost. He called out the culture of secrecy, noting that executives are afraid of what transparency might reveal. "People don't want to do that because they're scared of what it would do for their business."
Trending: Maker of a life-changing asthma device with 12,000+ patients waiting, FDA clearance, and a 67% drop in attacks — now <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">taking final investors at just $1.52 per share.</a>
To Cuban, that's more than just bad management—it's a moral failure. "This isn't the Dallas Mavericks," he said. "This is the health and welfare of our entire country."
And while he proudly calls himself a capitalist, he draws a line when it comes to healthcare. "You don't have to just grab every nickel that you can get when there's this at stake."
If the <a href="https://www.benzinga.com/25/03/44530674/mark-cuban-vows-to-revamp-us-healthcare-by-empowering-independent-pharmacies-wants-no-pharmacy-deserts">industry refuses to act on its own</a>, Cuban believes it's time for regulators to step in. Not to micromanage. Not to take over. Just to require the basics.
"You've got to open the books," he said.
He's pushing for laws that would force hospitals and insurers to disclose actual costs, margins, and spending—something he says should be standard practice in any business that <a href="https://www.benzinga.com/startups/25/02/43662970/mark-cuban-says-u-s-healthcare-is-horrific-calls-for-free-medical-school-to-fix-doctor-shortages-and-soaring-costs">deals with life-and-death decisions</a>. If transparency threatens the business model, Cuban's argument is simple: maybe that business shouldn't exist in the first place.
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
</ul>
Image: Shutterstock

Mark Cuban Says Health Insurance Shouldn't Exist — 'You Don't Have to Grab Every Nickel When It's the Health of the Entire Country at Stake'

AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) is gearing up to announce its quarterly earnings on Monday, 2025-04-21. Here's a quick overview of what investors should know before the release.
Analysts are estimating that AZZ will report an earnings per share (EPS) of $0.98.
Anticipation surrounds AZZ's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.12, which was followed by a 1.92% drop in the share price the next day.
Here's a look at AZZ's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.27</td>
<td>1.32</td>
<td>1.30</td>
<td>0.70</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.39</td>
<td>1.37</td>
<td>1.46</td>
<td>0.93</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-5.0%</td>
<td>6.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744995631_0.png" alt="eps graph" />
<h3>Tracking AZZ's Stock Performance</h3>
Shares of AZZ were trading at $82.01 as of April 16. Over the last 52-week period, shares are up 5.88%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Opinions on AZZ</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on AZZ.
Analysts have provided AZZ with 3 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $106.67, suggesting a potential 30.07% upside.
<h3>Analyzing Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Hayward Holdings, Griffon and CSW Industrials, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Hayward Holdings, with an average 1-year price target of $17.25, suggesting a potential 78.97% downside.</li>
<li>Analysts currently favor an Buy trajectory for Griffon, with an average 1-year price target of $96.5, suggesting a potential 17.67% upside.</li>
<li>Analysts currently favor an Neutral trajectory for CSW Industrials, with an average 1-year price target of $319.33, suggesting a potential 289.38% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
In the peer analysis summary, key metrics for Hayward Holdings, Griffon and CSW Industrials are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZZ</td>
<td>Buy</td>
<td>5.78%</td>
<td>$97.78M</td>
<td>3.31%</td>
</tr>
<tr>
<td>Hayward Holdings</td>
<td>Buy</td>
<td>17.45%</td>
<td>$168.00M</td>
<td>3.91%</td>
</tr>
<tr>
<td>Griffon</td>
<td>Buy</td>
<td>-1.68%</td>
<td>$264.28M</td>
<td>31.30%</td>
</tr>
<tr>
<td>CSW Industrials</td>
<td>Neutral</td>
<td>10.68%</td>
<td>$80.11M</td>
<td>2.60%</td>
</tr>
</tbody>
</table>

Key Takeaway:
AZZ ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, AZZ is at the bottom compared to its peers.
<h3>Get to Know AZZ Better</h3>
AZZ Inc is a provider of galvanizing and a variety of metal coating solutions and coil coating solutions to a broad range of end markets in North America. In its Metal Coatings segment, the company offers metal finishing services to protect against corrosion, such as hot dip galvanizing, spin galvanizing, powder coating, anodizing, and plating. The Precoat Metals Segment offers aesthetic and corrosion-resistant coatings for steel and aluminum coils.
<h3>AZZ: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: AZZ's revenue growth over a period of 3 months has been noteworthy. As of 30 November, 2024, the company achieved a revenue growth rate of approximately 5.78%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: AZZ's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 8.32%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): AZZ's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.31%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): AZZ's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.5%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: AZZ's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.88.
<a href="https://www.benzinga.com/quote/AZZ/earnings">To track all earnings releases for AZZ visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

A Preview Of AZZ's Earnings

AGNC Investment's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NYSE">AGNC</a>) short percent of float has risen 24.66% since its last report. The company recently reported that it has 58.04 million shares sold short, which is 6.47% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.33 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>AGNC Investment Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744995628_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AGNC Investment has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing AGNC Investment's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, AGNC Investment's peer group average for short interest as a percentage of float is 7.07%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

AGNC

How Do Investors Really Feel About AGNC Investment?

Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) is gearing up to announce its quarterly earnings on Monday, 2025-04-21. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Cathay General will report an earnings per share (EPS) of $0.95.
Anticipation surrounds Cathay General's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.04, leading to a 3.87% drop in the share price on the subsequent day.
Here's a look at Cathay General's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.08</td>
<td>0.95</td>
<td>0.94</td>
<td>0.98</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.12</td>
<td>0.97</td>
<td>0.96</td>
<td>0.98</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>2.0%</td>
<td>1.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1744995623_0.png" alt="eps graph" />
<h3>Cathay General Share Price Analysis</h3>
Shares of Cathay General were trading at $38.34 as of April 16. Over the last 52-week period, shares are up 5.49%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/CATY/earnings">To track all earnings releases for Cathay General visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CATY

A Look Ahead: Cathay General's Earnings Forecast

Yum Brands's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) short percent of float has fallen 10.89% since its last report. The company recently reported that it has 6.16 million shares sold short, which is 2.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Yum Brands Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744995623_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Yum Brands has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Yum Brands's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Yum Brands's peer group average for short interest as a percentage of float is 9.95%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is Yum Brands Gaining or Losing Market Support?

C3.ai's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) short percent of float has risen 3.1% since its last report. The company recently reported that it has 22.78 million shares sold short, which is 22.59% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>C3.ai Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744995618_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for C3.ai has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing C3.ai's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, C3.ai's peer group average for short interest as a percentage of float is 11.62%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into C3.ai's Recent Short Interest

In the current market session, TotalEnergies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) price is at $58.33, after a 0.86% spike. However, over the past month, the stock fell by 7.73%, and in the past year, by 19.47%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1744995616_0.png" alt="Past Year Chart" />

<h3>Comparing TotalEnergies P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
TotalEnergies has a lower P/E than the aggregate P/E of 29.93 of the Oil, Gas &amp; Consumable Fuels industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744995616_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for TotalEnergies

<a href="https://www.youtube.com/live/8E-dSoXo7wk?si=v7jMNzbAVIuT46p0">https://www.youtube.com/live/8E-dSoXo7wk?si=v7jMNzbAVIuT46p0</a>

Politics

Economics

President Trump Says U.S. Having Nice Conversations Going On With China

<a href="https://www.youtube.com/live/8E-dSoXo7wk">https://www.youtube.com/live/8E-dSoXo7wk</a>

President Trump Says We Will Take A Pass If Parties Make It Difficult To End War In Ukraine But Hopes It Does Not Come To That; Says He Doesn't Want To Say He's Walking Away From The Talks; Asked If Russia Is Playing Him, Says No One Is Playing Me; Says  We Have A Really Good Chance Of Getting Ukraine-Russia Deal

Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is doing just fine, thank you very much. While other streamers fight over scraps, the OG is <a href="https://www.benzinga.com/quote/NFLX/earnings">stacking subscribers, content, and cash</a> &#8211; and throwing punches with live sports and games too.
Fresh off a beat on both top and bottom lines for <a href="https://www.benzinga.com/general/entertainment/25/04/44877995/netflix-crushes-q1-says-its-working-hard-to-improve-and-expand-its-offering">the first quarter</a>, the stock surged above all key moving averages, flashing a &#8220;strongly bullish&#8221; signal across the board. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0418"><img loading="lazy" decoding="async" width="627" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/18104852/Screenshot-2025-04-18-at-8.18.35-PM.png" alt="" class="wp-image-878288" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/18104852/Screenshot-2025-04-18-at-8.18.35-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/18104852/Screenshot-2025-04-18-at-8.18.35-PM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0418">Chart created using Benzinga Pro</a>
As Ed Egilinsky, Managing Director at Direxion, put it: "NFLX is experiencing slight buying pressure"—but it's clear investors are feeling more than slightly confident.
Instead of obsessing over sub counts (which it&#8217;s no longer disclosing quarterly), Netflix focused on the future: "We remain optimistic about our 2025 slate," the company said, highlighting returning hits, surprises, and the highly anticipated "Squid Game" Season 3 &#8211; set to drop on June 27.
Read Also: <a href="https://www.benzinga.com/25/04/44881044/netflix-downplays-recession-fears-amid-market-volatility-triggered-by-trump-tariffs-co-ceo-greg-peters-raves-about-resilient-799-ad-plan-we-havent-seen-any-significant-changes">Netflix Confident Of Its &#8216;Incredible Entertainment Value&#8217; As Recession Fears Intensify, Greg Peters Says $7.99 Ad Plan Engagement Remains &#8216;Strong And Healthy&#8217;</a>
Not to be outdone, the company is also bringing NFL football to Christmas Day, and just launched its in-house ad tech, signaling it&#8217;s not just playing in the advertising arena—it's aiming to control the field.
And let's not forget games. "Squid Game: Unleashed" has already been a smash hit, and new content is syncing up with the show's return. In the battle for attention, Netflix isn't just streaming—it's scheming.
With the stock now trading at $973.03 &#8211; well above its eight, 20, 50 and 200-day SMAs (simple moving averages) &#8211; momentum looks unstoppable. And with 2025 revenue guidance locked in at up to $44.5 billion, Netflix is streaming confidence straight into investors&#8217; portfolios.
As the company puts it, it&#8217;s building "the most valued entertainment company for members, creators and shareholders." So far, mission very much accomplished.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/44869415/netflix-vs-the-enormous-eight-one-stocks-bull-run-amid-big-tech-blues">Netflix Vs. The Enormous Eight: One Stock&#8217;s Bull Run Amid Big Tech Blues</a></li>
</ul>
Image: Shutterstock/Vantage_DS

Analyst Color

Earnings Beats

Long Ideas

Technicals

Analyst Ratings

Tech

NFLX

Netflix Is Squid-Gaming The Market - And Winning

Editor's Note: The original story inaccurately suggested that Warren Buffett's Berkshire Hathaway had indirect exposure to Bitcoin ETFs. We regret the error. 
 Image via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

IBIT

MSTR

MTPLF

Article Removed Regarding Berkshire Hathaway's Alleged Exposure To Bitcoin ETFs (CORRECTED)

FirstCash Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCFS#NASDAQ">FCFS</a>) has outperformed the market over the past 15 years by 1.41% on an annualized basis producing an average annual return of 11.69%. Currently, FirstCash Hldgs has a market capitalization of $5.40 billion. 
Buying $100 In FCFS: If an investor had bought $100 of FCFS stock 15 years ago, it would be worth $516.99 today based on a price of $120.76 for FCFS at the time of writing.
<h3>FirstCash Hldgs's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744994713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FCFS

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

<a href="https://www.bloomberg.com/news/articles/2025-04-18/trump-studying-whether-removing-powell-is-option-hassett-says">https://www.bloomberg.com/news/articles/2025-04-18/trump-studying-whether-removing-powell-is-option-hassett-says</a>

Macro Economic Events

'Trump Studying Whether Removing Powell Is Option, Hassett Says'- Bloomberg

<ul>
<li>For years, Microsoft has been the leading software provider for U.S. government agencies, holding an 85% share of the market</li>
<li>But a new deal between Google and the U.S. General Services Administration may change that up</li>
<li>The deal, Google says, has the potential to save the federal government up to $2 billion</li>
</ul>
Microsoft has long been the primary software provider for federal government agencies, but <a href="https://www.reuters.com/technology/google-slashes-business-software-prices-us-federal-agencies-2025-04-10/">Reuters</a> reports that Google just secured a deal that could put an end to that reign.
According to the report, Google has offered a 71% discount as part of an agreement with the General Services Administration. If adopted, Google says the deal could save government agencies up to $2 billion.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
The deal comes at a time when President Donald Trump has been working to minimize federal spending. His administration installed Elon Musk as the de facto leader of the Department of Government Efficiency, tasking them with identifying and canceling unnecessary contracts and shrinking agencies.
The GSA, which is responsible for managing federal properties and services, was one of the first agencies targeted by DOGE. A spokesman for GSA told Reuters that, "The Workspace agreement marks a step forward in GSA&#8217;s work with Google and other companies to create cost savings for the federal government.&#8221;&nbsp;
Importantly, the deal will be based on the entire volume of the government, which could lead to more savings for it, Reuters reports. Previous deals, according to the report, have seen separate agencies get separate contracts with different discounts attached to each, making for a more chaotic and less structured system.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
Reuters reports that Google is hopeful that the deal, which will be effective through September, will open the door for more extensive government contracts in the future. In 2021, it was estimated by Reuters that Microsoft's share of the U.S. government's software market was 85%, making it the largest player in the space by far.&nbsp;
For some time now, Google has been working on taking a larger share of the consumer, enterprise, and government markets. Its addition of a host of AI features powered by its large language model, Gemini, to its workspace is a perfect example of these efforts.
But it seems Google is looking to change things up at Gemini. On April 2, it said that Sissie Hsiao, who led the development of Gemini, would be stepping down. It's been widely reported that she's set to be replaced by Josh Woodward, who currently leads Google Labs and oversaw the launch of NotebookLM. Demis Hassabis, the CEO of Google DeepMind, reportedly said in a memo to staff that the move will help the company focus on the future of Gemini and that Hsiao is not leaving the company, just stepping into a new role.&nbsp;
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
<li>Maker of a life-changing asthma device with 12,000+ patients waiting, FDA clearance, and a 67% drop in attacks — now <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">taking final investors at just $1.52 per share.</a></li>
</ul>
Image: Shutterstock

Personal Finance

Google Just Scored A Government Deal Based On 'The Volume Of The Entire Government' – And That's Bad News For Microsoft

Agnico Eagle Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) has outperformed the market over the past 5 years by 3.67% on an annualized basis producing an average annual return of 17.7%. Currently, Agnico Eagle Mines has a market capitalization of $61.49 billion. 
Buying $1000 In AEM: If an investor had bought $1000 of AEM stock 5 years ago, it would be worth $2,255.57 today based on a price of $122.21 for AEM at the time of writing.
<h3>Agnico Eagle Mines's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744993810_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Agnico Eagle Mines 5 Years Ago Would Be Worth Today

The housing market is witnessing a disparity between the number of sellers and potential buyers. 
What Happened: The main reason behind this imbalance is the affordability concerns among potential buyers, leading to a rise in inventory and possible price reductions, as per a report by&nbsp;Zillow.
According to the <a href="https://www.businessinsider.com/national-association-realtors-rules-commissions-zillow-home-search-pocket-listings-2025-4">report</a>, sellers listed over 375,000 homes in the previous month, a 32% surge from the month prior, and a 9% increase year-over-year. However, the growth in buyer activity did not keep pace with this surge, resulting in flat pending home sales compared to the previous year.
This mismatch led to a net increase of 110,000 listings, pushing the overall inventory up by&nbsp;19% year-over-year to 1.15 million,&nbsp;the highest since March 2020. Despite the low mortgage rates in March 2025, high home prices have deterred buyers, leading to higher mortgage payments.
Also Read: <a href="https://www.benzinga.com/news/24/12/42716239/where-to-invest-here-are-the-top-10-us-housing-market-hot-spots-for-2025">Where To Invest? Here Are The Top 10 US Housing Market Hot Spots For 2025</a>
Skylar Olsen, Zillow&#8217;s chief economist, told the outlet,&nbsp;&#8220;While sellers leaned on the&nbsp;gas, buyers didn&#8217;t keep up.&#8221; This resulted in&nbsp;23% of listings on Zillow&nbsp;experiencing a price reduction in March, the highest percentage since 2018.
However, Zillow&#8217;s Market Heat Index indicates that the housing market has largely favored sellers over the past five years, only shifting to a &#8220;sellers market&#8221; in March for the first time since June of the previous year.
Why It Matters: The current buyer-seller mismatch in the housing market is a clear indication of the affordability concerns among potential buyers. Despite the increase in listings and potential price cuts, high home prices continue to be a deterrent. 
This situation, if it persists, could lead to a significant shift in the housing market dynamics, with potential long-term impacts on both buyers and sellers. 
The role of factors such as mortgage rates and overall economic conditions will also be crucial in determining the future trajectory of the housing market.
Read Next
<a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42027218/could-trumps-housing-plans-reshape-the-real-estate-market" target="_blank" rel="noreferrer noopener">Could Trump's Housing Plans Reshape The Real Estate Market?</a>
Image: Shutterstock/Cherdchai101

Real Estate

For Sale, But No Takers: The US Housing Market's Awkward Standoff

Erik Prince, a businessman and longtime supporter of President Donald Trump, has reportedly agreed to help the Democratic Republic of Congo (DRC) secure and tax its <a href="https://www.benzinga.com/markets/commodities">vast mineral wealth</a>.
According <a href="https://www.reuters.com/world/trump-supporter-prince-reaches-deal-with-congo-help-secure-mineral-wealth-2025-04-17/">to</a> Reuters, he reached the agreement before the M23 rebel group <a href="https://www.benzinga.com/news/global/25/02/43573846/un-warns-about-escalating-conflict-dr-congo-as-rebels-seize-mining-center">launched a major offensive</a> in January 2025 that saw them seize key cities in eastern Congo, including Goma. Two sources close to Prince, a Congolese official, and two diplomats confirmed new discussions, focusing on improving tax collection and reducing cross-border smuggling of valuable minerals.
With the cash leaks in Congo's mining sector, there&#8217;s a desperate need for structure," said one source. Despite no confirmed links to the U.S. government or military, security contractors remain a possible option under future U.S. support frameworks.
Prince, best known as the founder of Blackwater—the private security firm implicated in the killing of Iraqi civilians in 2007—has operated in Africa for over a decade, providing logistics and security services for mining and oil companies. His companies have been active in Congo since 2015, though previous attempts to deploy contractors, including a 2023 proposal to send thousands to the conflict-ridden east, failed to materialize.
The DRC&#8217;s mineral wealth is staggering. The country holds an estimated 6 million metric tons of cobalt, over 57% of global reserves, essential for electric vehicle batteries. It also possesses around 75 million metric tons of copper, 150 million carats of diamonds, and vast gold, coltan, tin, and lithium deposits, most of which are extracted under poor oversight and often smuggled out of the country. KoBold Metals, a startup backed by billionaires Bill Gates and Jeff Bezos, has recently approached DRC, <a href="https://www.benzinga.com/25/03/44456007/gates-bezos-backed-startup-makes-move-for-dr-congos-lithium">inquiring about lithium mining</a>, while copper giant Freeport-McMoran (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) has floated the idea about returning to the jurisdiction it exited in 2020.
Smuggling conflict minerals has been a heated topic. The DRC accused and even <a href="https://www.benzinga.com/news/legal/24/12/42527087/dr-congo-fires-first-salvo-files-complaints-against-apple-over-conflict-minerals">sued Apple</a> before the French prosecutor dropped the charges, classifying them as "not sufficiently well-founded."
Sources say Prince's initial security deployment is expected in the Katanga province, particularly at copper mines near Kolwezi – a region allegedly losing up to $40 million per month in untracked mineral flows. Sources noted they expect contractors to avoid direct conflict zones, instead deploying alongside commodity inspection specialists to improve transparency and revenue collection.
Read Next: <a href="https://www.benzinga.com/25/04/44861734/newmont-completes-a-year-long-portfolio-optimization-process">Newmont Completes A Year-Long Portfolio Optimization Process</a>
Image: Shutterstock/esfera

Government

Rumors

Commodities

Global

Blackwater Founder Reaches a Security Deal With DR Congo

Simon Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) has outperformed the market over the past 5 years by 8.91% on an annualized basis producing an average annual return of 22.94%. Currently, Simon Property Group has a market capitalization of $49.08 billion. 
Buying $1000 In SPG: If an investor had bought $1000 of SPG stock 5 years ago, it would be worth $2,793.98 today based on a price of $150.41 for SPG at the time of writing.
<h3>Simon Property Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744992912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Simon Property Group 5 Years Ago Would Be Worth Today

Health Care

Press Releases

Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Management

Cue Biopharma Announces Strategic Organizational Transition

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Cue Biopharma to Host Business Update Call and Webcast

Cue Biopharma Announces Proposed Public Offering

IPOs

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Biomea Fusion

Cabaletta Bio

Cibus

Caribou Biosciences

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

I-MAB

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Inozyme Pharma

IO Biotech

Invivyd

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Kronos Bio

Seres Therapeutics

Metagenomi

Pyxis Oncology

Renovaro

Serina Therapeutics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Vistagen Therapeutics, Inc. - Common Stock

Comments

Cue Biopharma

Interés en corto

Cue Biopharma (NASDAQ:CUE) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL